NO20042904L - Anvendelse av norepinefrin-reopptakinhibitorer for behandling av kognitiv svikt - Google Patents

Anvendelse av norepinefrin-reopptakinhibitorer for behandling av kognitiv svikt

Info

Publication number
NO20042904L
NO20042904L NO20042904A NO20042904A NO20042904L NO 20042904 L NO20042904 L NO 20042904L NO 20042904 A NO20042904 A NO 20042904A NO 20042904 A NO20042904 A NO 20042904A NO 20042904 L NO20042904 L NO 20042904L
Authority
NO
Norway
Prior art keywords
treatment
reuptake inhibitors
norepinephrine reuptake
cognitive failure
cognitive
Prior art date
Application number
NO20042904A
Other languages
English (en)
Norwegian (no)
Inventor
Donald Richard Gehlert
Franklin Porter Bymaster
David Lee Mckinzie
Charles Renkin Yang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20042904L publication Critical patent/NO20042904L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20042904A 2001-12-11 2004-07-09 Anvendelse av norepinefrin-reopptakinhibitorer for behandling av kognitiv svikt NO20042904L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
PCT/US2002/036132 WO2003049724A1 (fr) 2001-12-11 2002-11-27 Utilisation d'inhibiteurs de recaptage de la noradrenaline dans le traitement de la defaillance cognitive

Publications (1)

Publication Number Publication Date
NO20042904L true NO20042904L (no) 2004-09-07

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042904A NO20042904L (no) 2001-12-11 2004-07-09 Anvendelse av norepinefrin-reopptakinhibitorer for behandling av kognitiv svikt

Country Status (26)

Country Link
US (1) US20050009925A1 (fr)
EP (1) EP1458368B1 (fr)
JP (1) JP2005517647A (fr)
KR (1) KR20040066895A (fr)
CN (1) CN1713900A (fr)
AU (1) AU2002352625A1 (fr)
BR (1) BR0213581A (fr)
CA (1) CA2467802A1 (fr)
CO (1) CO5590907A2 (fr)
CZ (1) CZ2004709A3 (fr)
DE (1) DE60223718T2 (fr)
EA (1) EA200400793A1 (fr)
EC (1) ECSP045145A (fr)
ES (1) ES2295435T3 (fr)
HR (1) HRPK20040528B3 (fr)
HU (1) HUP0402619A3 (fr)
IL (1) IL161989A0 (fr)
MX (1) MXPA04005716A (fr)
MY (1) MY136367A (fr)
NO (1) NO20042904L (fr)
NZ (1) NZ532065A (fr)
PL (1) PL369311A1 (fr)
SK (1) SK2442004A3 (fr)
TW (1) TW200300672A (fr)
WO (1) WO2003049724A1 (fr)
ZA (1) ZA200404274B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537521A (en) * 2002-08-14 2007-05-31 Pharmacia & Upjohn Co Llc Use of reboxetine for the treatment of hot flashes
WO2005011583A2 (fr) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Traitement de la rhinite allergique et de l'asthme
WO2005020975A2 (fr) * 2003-08-27 2005-03-10 Eli Lilly And Company Traitement de difficultes d'apprentissage et de troubles de la motricite faisant appel a des inhibiteurs de la recapture de la noradrenaline
CN1889940A (zh) * 2003-12-12 2007-01-03 伊莱利利公司 热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
AU2005238296A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317731A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Hyperhidrosis treatment
WO2011014475A2 (fr) * 2009-07-31 2011-02-03 National Taiwan University Traitement des symptômes négatifs de la schizophrénie associés à une neuréguline 1 défectueuse
JP6126531B2 (ja) * 2011-10-03 2017-05-10 国立研究開発法人国立長寿医療研究センター タウ凝集阻害剤
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
ES2246488T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC Reboxetina para tratar la migraña.
AP2002002481A0 (en) * 1999-10-13 2002-06-30 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors.
US20020161002A1 (en) * 2001-01-02 2002-10-31 Mel Epstein Use of catecholamine reuptake inhibitors to enhance memory
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション

Also Published As

Publication number Publication date
ZA200404274B (en) 2005-09-13
CA2467802A1 (fr) 2003-06-19
KR20040066895A (ko) 2004-07-27
PL369311A1 (en) 2005-04-18
US20050009925A1 (en) 2005-01-13
CN1713900A (zh) 2005-12-28
MY136367A (en) 2008-09-30
EP1458368A1 (fr) 2004-09-22
EP1458368B1 (fr) 2007-11-21
MXPA04005716A (es) 2004-12-06
SK2442004A3 (en) 2004-12-01
NZ532065A (en) 2007-03-30
AU2002352625A1 (en) 2003-06-23
ES2295435T3 (es) 2008-04-16
DE60223718D1 (de) 2008-01-03
WO2003049724A1 (fr) 2003-06-19
BR0213581A (pt) 2004-08-24
EA200400793A1 (ru) 2004-10-28
CO5590907A2 (es) 2005-12-30
IL161989A0 (en) 2005-11-20
CZ2004709A3 (cs) 2004-10-13
TW200300672A (en) 2003-06-16
ECSP045145A (es) 2004-07-23
DE60223718T2 (de) 2008-10-30
HRPK20040528B3 (en) 2006-03-31
HUP0402619A3 (en) 2008-04-28
JP2005517647A (ja) 2005-06-16
HUP0402619A2 (hu) 2005-03-29
HRP20040528A2 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
NO20014047D0 (no) Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
NO20044345L (no) NE- og 5-HT reopptakinhibitorer for behandling av viscerale smertesyndromer
NO20035609D0 (no) Fremgangsmåte for kontinuerlig naftabehandling
PT1605956E (pt) Administração de capsaicinóides para o tratamento da osteoartrite
NO20052058D0 (no) Behandling av influensa.
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
NO20045554L (no) Fremgangsmate for behandling av diabetes
NO20033803D0 (no) Karbamat for behandling av bevegelseslidelser
PT2314627T (pt) Método para o tratamento de esclerose múltipla
NO20033417D0 (no) Anvendelse av CD23-antagonister for behandling av neoplastiske forstyrrelser
IL161989A0 (en) Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
NO20043124L (no) Aminoindanderivater som serotonin -og norepinefrin-opptaksinhibitorer
NO20033804D0 (no) Karbamatforbindelser for behandling av smerte
NO20041968L (no) Anvendelse av cystationin
NO20042613L (no) Ny anvendelse for behandling av gastroosofagial refluks
SE0301854L (sv) Antiigensättningsbehandling
NO20042965L (no) Flytende anlegg for behandling av hydrokarboner
PT1268482E (pt) Piranoindois para o tratamento de glaucoma
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
DE602004030779D1 (de) Angehen des problems des schrittmachersyndroms
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application